Literature DB >> 3494542

Macrophage activation by interferon alpha + beta is associated with a loss of proliferative capacity: role of interferon alpha + beta in the regulation of macrophage proliferation and function.

B D Chen, F Najor.   

Abstract

Murine peritoneal exudate macrophages (PEM) can be induced by colony-stimulating factor (CSF-1) to undergo extensive proliferation and colony formation in vitro. In the presence of interferon alpha + beta (IFN alpha + beta) the proliferative capacity of PEM was greatly suppressed in a dose-dependent manner. The antiproliferative activity of IFN alpha + beta appears to be noncytocidal and reversible at low concentrations. At higher concentrations, exposure to IFN alpha + beta was sufficient to cause growth inhibition in PEM. Tissue-derived PEM were at least 25-fold more sensitive than bone marrow GM-CFC to the antiproliferative activity of IFN alpha + beta. The fact that bone marrow-derived adherent cells also exhibited a higher degree of sensitivity than the less differentiated nonadherent counterparts suggests that the primary targets of IFN alpha + beta are cells derived from a later stage of development. Concomitantly with the loss of proliferative activity, both the tumoricidal and Fc receptor-mediated phagocytic activities in IFN alpha + beta treated PEM were greatly enhanced. These effects could be completely neutralized by the addition of anti-IFN alpha + beta immunoglobulin, indicating that they are mediated by the same molecule. This remarkable dichotomy in the actions of IFN alpha + beta (stimulates functional activities but suppresses proliferative capacity) suggests that IFN alpha + beta may play a role in the regulation of macrophage production and function.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3494542     DOI: 10.1016/0008-8749(87)90177-8

Source DB:  PubMed          Journal:  Cell Immunol        ISSN: 0008-8749            Impact factor:   4.868


  6 in total

1.  Combined activation of murine lymphocytes with staphylococcal enterotoxin and interleukin-2 results in additive cytotoxic activity.

Authors:  H Belfrage; P Bhiladvala; G Hedlund; M Dohlsten; T Kalland
Journal:  Cancer Immunol Immunother       Date:  1994-04       Impact factor: 6.968

2.  Active specific immunotherapy with vaccinia colon oncolysate enhances the immunomodulatory and antitumor effects of interleukin-2 and interferon alpha in a murine hepatic metastasis model.

Authors:  P J Arroyo; J A Bash; M K Wallack
Journal:  Cancer Immunol Immunother       Date:  1990       Impact factor: 6.968

3.  Inhibition of macrophage-induced, antigen-specific T-cell proliferation by poly I:C role of suppressor macrophages.

Authors:  D A Kirschmann; X He; D M Murasko
Journal:  Immunology       Date:  1994-06       Impact factor: 7.397

Review 4.  The role of interferons in the treatment of malignant neoplasms.

Authors:  J R Murren; A C Buzaid
Journal:  Yale J Biol Med       Date:  1989 May-Jun

5.  DGCR8 deficiency impairs macrophage growth and unleashes the interferon response to mycobacteria.

Authors:  Barbara Killy; Barbara Bodendorfer; Jörg Mages; Kristina Ritter; Jonathan Schreiber; Christoph Hölscher; Katharina Pracht; Arif Ekici; Hans-Martin Jäck; Roland Lang
Journal:  Life Sci Alliance       Date:  2021-03-26

6.  Recombinant human interferon alpha 2b prevents and reverses experimental pulmonary hypertension.

Authors:  Eileen M Bauer; Han Zheng; Michael T Lotze; Philip M Bauer
Journal:  PLoS One       Date:  2014-05-16       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.